Copenhagen, September 29, 2012, MC2 Biotek, an emerging specialty pharmaceutical company specialized in dermatology and ophthalmology, announced today that Moorfields Pharmaceuticals makes MC2-03 PAD ™ Eye Drop (ciclosporin 0.06%) available for hospitals and pharmacies in the UK as a “Special”.
Products which are unlicensed and are prescribed for individuals are called “Specials”. The medical need in the UK for an eye drops containing ciclosporin has been identified by Moorfields Pharmaceuticals. MC2-03 PAD ™ Eye Drops will be available as a 10mL multidose bottle. Indications for use may include management of severe dry eye syndromes, severe allergic eye diseases, and prevention of corneal graft rejection.
Jesper J. Lange, President of MC2 Biotek said: “We are pleased that MC2-03 PAD ™ Eye Drop is now available to treat people with severe conditions of the eye through the “Special” status in the UK. We will continue to work to make this innovative ocular formulation of ciclosporin available to people who can benefit from it“.
About MC2-03 PAD ™ Eye Drop
MC2 Biotek is developing MC2-03 for the treatment of dry eye disease, a drug candidate derived from its PAD ™ Technology platform.